Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late Recurrence

Clin Lung Cancer. 2016 Sep;17(5):e169-e172. doi: 10.1016/j.cllc.2016.03.006. Epub 2016 Mar 30.

Authors

Xin Gao¹, Paul A VanderLaan², Alexandra S Bailey³, Daniel B Costa⁴

Affiliations

¹ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
² Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
³ Dana-Farber Community Cancer Care, Weymouth, MA.
⁴ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address: dbcosta@bidmc.harvard.edu.

PMID: 27103378
DOI: 10.1016/j.cllc.2016.03.006

No abstract available

Keywords: Metachronous; Next-generation sequencing; Recurrent; Small cell lung cancer; TP53.

Publication types

Case Reports
Research Support, N.I.H., Extramural

MeSH terms

Aged
Antineoplastic Agents / therapeutic use
Diagnosis, Differential
Female
High-Throughput Nucleotide Sequencing / methods*
Humans
Lung Neoplasms / diagnosis
Lung Neoplasms / genetics*
Neoplasm Recurrence, Local / diagnosis
Neoplasm Recurrence, Local / genetics*
Neoplasms, Second Primary / diagnosis
Neoplasms, Second Primary / genetics*
Small Cell Lung Carcinoma / diagnosis
Small Cell Lung Carcinoma / genetics*
Tomography, X-Ray Computed

Substances

Antineoplastic Agents